Eli Lilly’s CEO promises not to raise insulin prices
Eli Lilly & Co. won’t raise prices on any insulin products now on the market, Chief Executive Officer Dave Ricks told Senator Bernie Sanders at a hearing with big pharma executives as drugmakers come under increased scrutiny over soaring costs.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Joe Biden applauds Novo Nordisk for insulin price reductions
For subscribers
Novo Nordisk to reduce insulin prices by up to 75% in the US
For subscribers